(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 October 2020 (22.10.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/212594 A1

(51) International Patent Classification:
A61P 35/00 (2006.01) *A61K 47/10* (2017.01)
A61K 31/216 (2006.01)

(21) International Application Number:
PCT/EP2020/060900

(22) International Filing Date:
17 April 2020 (17.04.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1905477.4 17 April 2019 (17.04.2019) GB

(71) Applicant: **ONCOPEPTIDES AB** [SE/SE]; Västra Trädgårdsgatan 15, Stockholm 111 53 (SE).

(72) Inventors: **LEHMANN, Fredrik**; c/o Oncopeptides AB, Västra Trädgårdsgatan 15, Stockholm 111 53 (SE). **TEODOROVIC, Peter**; c/o Oncopeptides AB, Västra Trädgårdsgatan 15, Stockholm 111 53 (SE).

(74) Agent: **ABEL & IMRAY**; Westpoint Building, James Street West, Bath Bath and North East Somerset BA1 2DA (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: NOVEL FORMULATIONS COMPRISING MELFLUFEN




Figure 1

(57) Abstract: The invention provides a pharmaceutical formulation comprising (or consisting essentially of) the following components: i) melflufen, or a salt thereof; ii) propylene glycol; iii) optionally one or more physiologically acceptable aqueous solvent(s); and iv) optionally one or more additional therapeutic agent(s); or a pharmaceutical formulation comprising (or consisting essentially of) the following components: i) melflufen, or a salt thereof; ii) polyethylene glycol; iii) optionally one or more physiologically acceptable aqueous solvent(s); and iv) optionally one or more additional therapeutic agent(s). The invention also provides methods for preparing the pharmaceutical formulations of the invention, kits and uses of the pharmaceutical formulations of the invention.

WO 2020/212594 A1